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subsequent hyperkeratosis, as demon-
strated in the Olmsted syndrome
caused by TRPV3 mutations (Lin et al.,
2012). As TRPV4 and AQP5 were both
expressed in eccrine sweat glands
and keratinocytes (Delany et al., 2001;
Guler et al., 2002; Nejsum et al.,
2002; Blaydon et al., 2013), it is
reasonable to speculate that palmoplan-
tar hyperhidrosis and hyperkeratosis
in PPKB were, at least partly, due
to the gain-of-function effect of the
AQP5Asn123Tyr/TRPV4 complex. Our
studies linked a keratotic and hyper-
hidrotic disorder with the mutation of a
water channel, and indicated PPKB as a
previously unreported kind of skin
channelopathy.
Note: As we were preparing this
manuscript, Dr David Kelsell reported
several mutations of AQP5 in patients
with PPKB at the 2013 International
Investigative Dermatology Meeting in
Edinburgh, UK.
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TO THE EDITOR
Familial cutaneous malignant melanoma
(CMM) accounts for B10% of all CMM
cases (Hayward, 2003; Hansson, 2008).
The most common known high-pene-
trance susceptibility gene for familial
CMM development is CDKN2A, a
tumor suppressor gene on chromosome
9p21 that encodes two distinct proteins:
p16INK4A and p14ARF by alternative
splicing of two separate first exons, 1a
and 1b, respectively (Hansson, 2008).
In several countries, specific founder
mutations account for most of the germline
CDKN2A alterations. For instance,
p.R112_L113insR in Sweden and c.225-
243del19 in the Netherlands account for
B90% of familial mutations. Italy, Spain,
and France share their most common
mutation (p.G101W), while p.M53I,
c.IVS2-105A4G, p.R24P and p.L32P are
the most frequent mutations in Australia
and the UK (Goldstein et al., 2006).
BRAF and NRAS are the most
frequently somatically altered oncogenesAccepted article preview online 14 June 2013; published online 18 July 2013
Abbreviation: CMM, cutaneous malignant melanoma
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in CMM, with BRAF mutations detected
in B50% and NRAS mutations in
B20% of sporadic CMMs (Lee et al.,
2011). The RAS–RAF–MEK–ERK and the
PI3K-Akt pathways are commonly
activated in melanomas and occur even
in the absence of BRAF and NRAS
mutations (Fecher et al., 2008).
The purpose of this study was to
investigate whether inheritance of the
high-penetrance susceptibility gene
CDKN2A can affect the prevalence of
somatic BRAF/NRAS mutations in famil-
ial CMM. We also wanted to determine
if there is a correlation between the
expression of phosphorylated (p)-ERK
and phosphorylated (p)-Akt and germ-
line CDKN2A status. The study was
performed as a collaborative investiga-
tion within the GenoMEL consortium
(www.genomel.org).
Formalin-fixed paraffin-embedded
primary familial CMMs were collected
from eight centers in Europe and Aus-
tralia. Patient and tumor features are
shown in Table 1. In total, 135 familial
CMMs from 128 patients were success-
fully analyzed for mutations in BRAF
and/or NRAS, 89 from patients with
germline CDKN2A mutations and 46
from patients without germline
CDKN2A mutations. Six patients had
multiple primary tumors. For compari-
son purposes, we also included a con-
trol group consisting of 50 primary
sporadic CMMs matching the familial
cohort (Table 1). Methods used (Laser
capture microdissection, sequencing of
BRAF exon 15 and NRAS exon 2 and
pERK/pAkt immunohistochemistry) were
as previously described (Omholt et al.,
2011). Fisher’s exact test, Kruskal–
Wallis rank or Mann–Whitney tests
was used to test association of BRAF
and NRAS mutation with germline
CDKN2A status and patient and tumor
characteristics. This study was approved
by Ethics Review Boards of each parti-
cipating center.
BRAF and NRAS mutations were
identified in 43% and 11% of familial
CMMs, respectively (Table 2). In no case
were BRAF and NRAS mutations found
to coexist in the same tumor. There was
no significant difference in BRAF and
NRAS mutation frequencies between
tumors from patients with and without
germline CDKN2A alterations (Table 2).
There was also no difference in BRAF
mutation frequency between tumors
with CDKN2A mutations disrupting
both p16INK4A and p14ARF and tumors
with CDKN2A mutations affecting
p16INK4A only. With respect to different
types of germline CDKN2A mutations,
BRAF mutations were found in 5 of 8
p.M53I (62%), 11 of 24 p.R112_L113
insR (46%), 3 of 8 p.G101W (37%), and
7 of 20 c.225_243del19 (35%) altered
tumors. NRAS mutations were observed
in 1 of 8 p.M53I (12%), 3 of 21
p.R112_L113insR (14%), and 2 of 20
c.225_243del19 (10%) altered tumors.
No NRAS mutations were detected in
Table 1. Clinicopathological data of familial (n¼ 128) and sporadic (n¼ 50)
melanoma patients
Familial patients
Clinicopathological features CDKN2A mutated CDKN2A wt Sporadic patients P-value1
Median age, years (range) 45 (18–86) 50 (20–82) 50 (21–76) 0.130
Gender 0.855
Male 39 (46.4) 23 (52.3) 24 (48.0)
Female 45 (53.6) 21 (47.7) 26 (52.0)
Anatomical site, n (%) 0.337
Head and neck 9 (10.7) 1 (2.3) 5 (10.0)
Trunk 28 (33.3) 21 (47.7) 15 (30.0)
Upper extremities 16 (19.1) 9 (20.4) 15 (30.0)
Lower extremities 27 (32.1) 12 (27.3) 15 (30.0)
Data missing 4 (4.8) 1 (2.3) 0 (0.0)
Subtype, n (%) 0.141
SSM 57 (67.9) 30 (68.2) 38 (76.0)
NM 10 (11.9) 6 (13.6) 10 (20.0)
Other2 8 (9.5) 2 (4.6) 0 (0.0)
Data missing 9 (10.7) 6 (13.6) 2 (4.0)
Clark level, n (%) 0.188
I 4 (4.8) 0 (0.0) 0 (0.0)
II 27 (32.1) 15 (34.1) 10 (20.0)
III 28 (33.3) 19 (43.1) 27 (54.0)
IV 20 (23.8) 8 (18.2) 9 (18.0)
V 1 (1.2) 1 (2.3) 2 (4.0)
Data missing 4 (4.8) 1 (2.3) 2 (4.0)
Median thickness, mm 0.7 (0.1–14.2) 0.9 (0.1–5.0) 1.2 (0.3–10.0) 0.093
Ulceration, n (%) 0.752
Present 7 (8.3) 6 (13.6) 9 (18.0)
Absent 32 (38.1) 20 (45.5) 27 (54.0)
Data missing 45 (53.6) 18 (40.9) 14 (28.0)
Abbreviations: NM, nodular melanoma; SSM, superficial spreading melanoma; wt, wild type.
1P-value is for comparison among the three groups.
2Other includes nevoid, lentigo maligna, and unclassified melanomas.
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eight tumors with the p.G101W
mutation.
In six familial patients, more than one
primary melanoma was analyzed. In
four cases, multiple tumors from the
same patient had identical BRAF and
NRAS genotypes. However, in one
patient with three melanomas all
tumors had different BRAF geno-
types, and in another patient with two
tumors the NRAS genotype differed
(Supplementary Table S1 online).
Of 55 familial tumors with BRAF
mutations, 51 had the V600E mutation.
Other observed BRAF mutations
included V600K (n¼ 3) and one tandem
V600E (c.1799TG4AA). One tumor
had two different BRAF mutations
(V600E and K601E), and another
contained a 12 base-pair deletion
(c.1802_1813del12) in addition to a
V600E change. The identified NRAS
mutations included Q61K (n¼ 8),
Q61R (n¼4), Q61L (n¼ 1), and Q61H
(n¼ 1).
The tumor thickness varied signifi-
cantly among BRAF mutated (1.0 mm),
NRAS mutated (1.4 mm), and BRAF/
NRAS wild-type familial CMMs
(0.6 mm; P¼0.004; Supplementary
Table S2 online). Other examined fea-
tures showed no association with BRAF
and NRAS mutation status (Supplemen-
tary Table S2 online).
Expression of pERK and pAkt was
observed in 65% and 46% of familial
CMMs, respectively, but showed no
association with CDKN2A mutation
status (Supplementary Table S3 online).
Similar frequencies of pERK and
pAkt expression were detected in the
sporadic cohort (Supplementary Table
S3 online).
In the sporadic cohort, BRAF muta-
tions were detected in 41% and NRAS
mutations were detected in 12%. Thus,
the frequency of BRAF and NRAS muta-
tions in sporadic CMMs did not differ
significantly from that identified in
familial CMMs (Table 2). Similar to a
trend observed in the familial tumors,
age at diagnosis differed significantly
among patients with BRAF mutated (43
years), NRAS mutated (58 years), and
BRAF/NRAS wild-type sporadic tumors
(59 years; P¼0.029).
We have previously analyzed an
independent set of 19 familial CMMs
with different germline CDKN2A altera-
tions and found a BRAF and NRAS
mutation frequency of 37% and 16%,
respectively, consistent with the current
report (Jovanovic et al., 2010). Eskandar-
pour et al. (2003) earlier analyzed an
independent set of familial CMMs with
the Swedish p.R112_L113insR founder
mutation and identified NRAS mutations
in 94% (15/16) of the tumors. In the
present study, we observed an NRAS
mutation rate of 14% in tumors with the
p.R112_L113insR mutation. The reason
for the discrepancy in NRAS mutation
frequency between the studies is
unclear, but may be related to chance
or the use of different methodologies
(single-strand conformation polymor-
phism vs sequencing).
In conclusion, this is the largest study
to date on somatic mutations in familial
CMM in individuals with defined germ-
line CDKN2A status. We found that
different inherited variants of CDKN2A
have no effect on the prevalence of
BRAF and NRAS mutations in familial
CMM. However, the number of patients
recruited to the study was too small to
generate sufficient statistical power to
definitively assess the association of the
somatic BRAF/NRAS mutations and
specific germline CDKN2A mutations.
Our results revealed that BRAF and
NRAS mutation frequencies in familial
CMMs were similar to those identified
in the sporadic control group and to
what has previously been reported in
primary sporadic CMMs (Lee et al.,
2011). Thus, our study suggests that
although germline CDKN2A mutations
in familial CMM predispose to develo-
pment of melanomas, the somatic
genetic alterations are similar to those
implicated in sporadic cases. The simi-
larity between familial and sporadic
CMMs with respect to somatic muta-
tion pattern implies that novel-targeted
drugs towards mutated BRAF and/or
MEK are expected to have a similarly
important role in familial as in sporadic
CMMs.
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Table 2. Frequency of BRAF and NRAS mutations in familial and sporadic
melanoma tumors
Tumors with BRAF mutations Tumors with NRAS mutations
Tumor n % n %
Familial 55/1291 43 14/1251 11
CDKN2A mutated 38/85 45 7/80 9
Exon 1a 6/12 50 0/11 0
Exon 1b 3/5 60 0/5 0
Exon 2 27/64 42 7/60 12
Introns 1 and 2 2/4 50 0/4 0
CDKN2A wild-type 17/44 39 7/45 15
Sporadic 20/49 41 6/50 12
1Overall, 135 familial cutaneous malignant melanomas were included in the study.
DNA from 119 tumors was successfully screened for both BRAF and NRAS, whereas for 10 tumors,
DNA amplification was successful for BRAF but not for NRAS, and for another six tumors, DNA was
amplified only for NRAS.
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TO THE EDITOR
Primary cutaneous large B-cell lym-
phoma, leg type (PCLBCL-LT) is an
aggressive cutaneous lymphoma with a
5-year overall survival of approximately
40%. Because of its aggressive nature,
the treatment of first choice is anthracy-
clin-based chemotherapy combined
with rituximab (Senff et al., 2008). How-
ever, patients often show a progressive
disease course despite treatment with
polychemotherapy. Furthermore, owing
to age and comorbidity, not all patients
are eligible for this treatment. Therefore,
new and additional therapies for
PCLBCL-LT are necessary, with a focus
on more specific, targeted therapies
with fewer side effects than
conventional chemotherapy. At the
mRNA expression level, PCLBCL-LT
resembles nodal activated B-cell-type
diffuse large B-cell lymphoma (ABC-
DLBCL), including strong expression of
known targets of the NF-kB pathway,
such as IRF4 (Davis et al., 2001;
Hoefnagel et al., 2005). In nodal
ABC-DLBCL, increased NF-kB activity
has a role in its pathogenesis through
transcriptional activation of genes
involved in cellular survival mechani-
sms. Previous studies demonstrated that
mutations in multiple genes can cause
deregulation of NF-kB signaling in nodal
ABC-DLBCL (Compagno et al., 2009).
The genes most frequently affected
by these NF-kB-activating genetic
aberrations are TNFAIP3 (A20), CD79B,
CARD11 (CARMA1), and MYD88, which
we investigated in 10 cases of PCLBCL-
LT (Supplementary Table S1 online).
TNFAIP3 (A20) is a tumor suppressor
gene, downregulating NF-kB signaling
by targeting several proteins involved in
the activation of this pathway. By quan-
titative PCR, transcriptional levels of
TNFAIP3 varied in our PCLBCL-LT cases
(Supplementary Figure S1 online), and
therefore we investigated potential
underlying mechanisms for this variation.
Four cases with relatively low mRNA
expression levels showed heterozygous
deletion of the gene region by high-
density fine-tiling comparative genomic
hybridization. Homozygous deletions as
observed in 10% of nodal ABC-DLBCL
(Compagno et al., 2009) were not found.
In cases without deletion of TNFAIP3,
but displaying relatively low levels of
mRNA, we could not detect epigenetic
silencing through promoter hypermethy-
lation, as was encountered in approxi-
mately 40% of nodal ABC-DLBCL
(Honma et al., 2009). Possibly, in these
cases, reduced mRNA expression was
regulated by altered transcription factorAccepted article preview online 13 June 2013; published online 18 July 2013
Abbreviations: ABC-DLBCL, activated B-cell-type diffuse large B-cell lymphoma; cDNA, complementary
DNA; PCLBCL-LT, primary cutaneous large B-cell lymphoma, leg type
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